Jane Street Group Llc decreased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 66.3% based on its latest 2018Q4 regulatory filing with the SEC. Jane Street Group Llc sold 28,975 shares as the company’s stock rose 8.95% with the market. The institutional investor held 14,725 shares of the health care company at the end of 2018Q4, valued at $1.07 million, down from 43,700 at the end of the previous reported quarter. Jane Street Group Llc who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be less bullish one the $9.86 billion market cap company. The stock increased 1.47% or $1.34 during the last trading session, reaching $92.79. About 752,221 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 28.65% since April 8, 2018 and is downtrending. It has underperformed by 33.02% the S&P500. Some Historical ALNY News: 21/03/2018 – ALNYLAM PHARMACEUTICALS INC – REGENERON WILL CONTRIBUTE RESEARCH ON HEPATOCYTE-EXPRESSED, GENETICALLY-VALIDATED HSD17B13 TARGET; 20/04/2018 – ALNYLAM PHARMACEUTICALS – ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL; 26/03/2018 – Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi; 07/05/2018 – The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad; 08/05/2018 – Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics; 12/03/2018 – Busy Sanofi takes a pass on one of Alnylam’s rare disease drugs, FDA offers ‘breakthrough’ status for PhIII $SNY $ALNY; 24/04/2018 – ALNYLAM PHARMACEUTICALS INC – PATISIRAN DEMONSTRATED IMPROVEMENT IN MULTIPLE QUALITY OF LIFE MEASURES, COMPARED TO PLACEBO; 23/04/2018 – ALNYLAM GETS POS OPINION FOR ORPHAN DRUG IN EU ON ALN-TTRSC02; 21/03/2018 – The PCSK9 of NASH? Regeneron and Alnylam join forces to tackle a promising target for severe liver diseases $REGN $ALNY; 26/03/2018 – ALNYLAM GETS EMA PRIME DESIGNATION FOR ACCELERATED LUMASIRAN,

Goodwin Daniel L increased its stake in Qts Rlty Tr Inc (QTS) by 48.98% based on its latest 2018Q4 regulatory filing with the SEC. Goodwin Daniel L bought 14,400 shares as the company’s stock rose 4.50% with the market. The institutional investor held 43,800 shares of the consumer services company at the end of 2018Q4, valued at $1.62 million, up from 29,400 at the end of the previous reported quarter. Goodwin Daniel L who had been investing in Qts Rlty Tr Inc for a number of months, seems to be bullish on the $2.86 billion market cap company. The stock increased 0.50% or $0.23 during the last trading session, reaching $46.07. About 530,246 shares traded or 3.66% up from the average. QTS Realty Trust, Inc. (NYSE:QTS) has risen 27.98% since April 8, 2018 and is uptrending. It has outperformed by 23.61% the S&P500. Some Historical QTS News: 15/03/2018 – QTS Renews Leases Representing 19 Megawatts with Two Hyperscale Anchor Tenants in Atlanta-Metro Data Center; 02/04/2018 – Clint Heiden Joins QTS as Chief Revenue Officer; 20/04/2018 – Leading Proxy Advisory Firm Glass Lewis & Co. Recommends that QTS Stockholders Vote “FOR” ALL Eight QTS directors at the Company’s 2018 Annual Meeting; 20/04/2018 – QTS SAYS GLASS LEWIS BACKS ITS DIRECTOR NOMINATIONS; 17/04/2018 – Investor Expectations to Drive Momentum within Kirkland’s, The Walt Disney, The Kraft Heinz, Southwestern Energy, QTS Realty Tr; 30/04/2018 – Land & Buildings: QTS Board Should Be Focused on Separate Chmn and CEO Roles; 15/05/2018 – Waddell & Reed Financial Inc. Exits Position in QTS Realty; 21/04/2018 – DJ QTS Realty Trust Inc Class A, Inst Holders, 1Q 2018 (QTS); 20/04/2018 – QTS:GLASS LEWIS RECOMMENDS OPPOSING EXECUTIVE COMPENSATION VOTE; 25/04/2018 – QTS REAFFIRMS FORECAST

Investors sentiment increased to 1.07 in Q4 2018. Its up 0.01, from 1.06 in 2018Q3. It is positive, as 34 investors sold ALNY shares while 70 reduced holdings. 28 funds opened positions while 83 raised stakes. 89.04 million shares or 2.44% more from 86.92 million shares in 2018Q3 were reported. Sector Gamma As invested in 59,437 shares. Vigilant Capital Mngmt Limited Com reported 500 shares stake. Stanley has invested 0.06% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Millennium Mngmt Ltd Com, a New York-based fund reported 11,373 shares. Rhumbline Advisers reported 90,596 shares stake. 17,448 were accumulated by Invesco Limited. Voya Investment Mngmt Ltd, Georgia-based fund reported 56,222 shares. 174,000 were accumulated by Savings Bank Of Nova Scotia. Guggenheim Cap Ltd Liability holds 0.04% or 63,974 shares in its portfolio. Manufacturers Life Insur The, Ontario – Canada-based fund reported 214,491 shares. Sumitomo Mitsui stated it has 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 9,704 are owned by Zeke Cap Advsr Lc. Northern Corporation has 531,648 shares for 0.01% of their portfolio. State Of Wisconsin Invest Board owns 35,237 shares. Amp Capital Limited reported 27,626 shares.

Jane Street Group Llc, which manages about $47.50B US Long portfolio, upped its stake in Ishares Tr (Call) (IVV) by 10,300 shares to 13,600 shares, valued at $3.42M in 2018Q4, according to the filing. It also increased its holding in Vaneck Vectors Etf Tr by 30,768 shares in the quarter, for a total of 65,356 shares, and has risen its stake in Lennar Corp (NYSE:LEN).

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on May, 2. They expect $-2.15 EPS, down 52.48% or $0.74 from last year’s $-1.41 per share. After $-2.09 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 2.87% negative EPS growth.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Nasdaq.com which released: “2 Biotechs With Big Dates in April – Nasdaq” on March 30, 2019, also Nasdaq.com with their article: “Add Up The Pieces: IYH Could Be Worth $217 – Nasdaq” published on March 14, 2019, Nasdaq.com published: “Alnylam’s (ALNY) Impressive Pipeline Drives Share Price – Nasdaq” on March 18, 2019. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Nasdaq.com and their article: “Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report? – Nasdaq” published on March 09, 2019 as well as Nasdaq.com‘s news article titled: “Alnylam Pharmaceuticals is Now Oversold (ALNY) – Nasdaq” with publication date: November 14, 2018.

Goodwin Daniel L, which manages about $190.58 million US Long portfolio, decreased its stake in Jpmorgan Chase & Co (NYSE:JPM) by 50,000 shares to 26,550 shares, valued at $2.59 million in 2018Q4, according to the filing.

Since November 2, 2018, it had 1 insider purchase, and 0 sales for $685,475 activity.

More notable recent QTS Realty Trust, Inc. (NYSE:QTS) news were published by: Streetinsider.com which released: “QTS Realty Trust (QTS) Prices 6.75M Class A Share Common Offering at $41.50/S – StreetInsider.com” on February 27, 2019, also Seekingalpha.com with their article: “QTS announces $240M JV for Virginia data center with Q4 results – Seeking Alpha” published on February 25, 2019, Prnewswire.com published: “QTS Realty Trust, Inc. Appoints Wayne Rehberger to Board of Directors – PRNewswire” on March 13, 2019. More interesting news about QTS Realty Trust, Inc. (NYSE:QTS) were released by: Bizjournals.com and their article: “Massive data center set for Hillsboro – Portland Business Journal” published on May 29, 2018 as well as Prnewswire.com‘s news article titled: “QTS Celebrates Sales Channel Achievements with Annual Partner of the Year Awards – PRNewswire” with publication date: March 28, 2019.